Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

OBJECTIVES: To assess the safety and efficacy of interleukin (IL)−6 blockade with sarilumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation. METHODS: We conducted an open-label study of sarilumab in severe COVID-19 pneumonia (PaO(2)/FiO(2) <300 mm Hg) with hyperinflammat...

Descripción completa

Detalles Bibliográficos
Autores principales: Della-Torre, Emanuel, Campochiaro, Corrado, Cavalli, Giulio, De Luca, Giacomo, Napolitano, Angela, La Marca, Salvatore, Boffini, Nicola, Da Prat, Valentina, Di Terlizzi, Gaetano, Lanzillotta, Marco, Rovere Querini, Patrizia, Ruggeri, Annalisa, Landoni, Giovanni, Tresoldi, Moreno, Ciceri, Fabio, Zangrillo, ALberto, De Cobelli, Francesco, Dagna, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509526/
https://www.ncbi.nlm.nih.gov/pubmed/32620597
http://dx.doi.org/10.1136/annrheumdis-2020-218122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509526/
https://www.ncbi.nlm.nih.gov/pubmed/32620597
http://dx.doi.org/10.1136/annrheumdis-2020-218122

Ejemplares similares